Key Highlights

  • On 10 August 2026 majority-owned Subsidiary Cytolytix received notice that the European Patent Office intends to grant a second core patent covering its anti-cancer peptide platform.
  • That follows a first European grant in May, a £1.155m fundraise the same month, and the exercise of an option over a McGill University helicase inhibitor in June.
  • Set against that activity is a stark balance sheet: year-end cash of under £0.8m, an auditor's going-concern warning and a Market Capitalisation of roughly £1.85m.
  • The 10 August 2026 announcement confirmed that the EPO intends to grant European patent application 20793085.0, "Polyleucine-Based Peptides As Anti-Cancer Agents", licensed from King's College London.
  • It sits alongside the "Nanoparticle for Anti-Cancer Peptides and Uses Thereof" patent granted in May 2026, giving the CLX001 programme two core European patents.

ValiRx PLC (LSE:VAL) has spent eighteen months shrinking and restructuring itself into something quite different from the clinical-stage drug developer of a few years ago. The question now is whether the new model, in which the London-listed group evaluates university science in its own laboratory and spins promising Assets into separately funded subsidiaries, can create value before the cash runs out again.

On 10 August 2026 majority-owned subsidiary Cytolytix received notice that the European Patent Office intends to grant a second core patent covering its anti-cancer peptide platform. That follows a first European grant in May, a £1.155m fundraise the same month, and the exercise of an option over a McGill University helicase inhibitor in June. Set against that activity is a stark balance sheet: year-end cash of under £0.8m, an auditor's going-concern warning and a market capitalisation of roughly £1.85m.

Second European patent for Cytolytix strengthens the licensing case

The 10 August 2026 announcement confirmed that the EPO intends to grant European patent application 20793085.0, "Polyleucine-Based Peptides As Anti-Cancer Agents", licensed from King's College London. It sits alongside the "Nanoparticle for Anti-Cancer Peptides and Uses Thereof" patent granted in May 2026, giving the CLX001 programme two core European patents.

ValiRx also disclosed that on 26 May 2026 it filed a further application covering a second-generation, lipid-based delivery platform, with data showing the formulation induces immunogenic cell death in triple negative breast cancer cells. Chief executive Dr Mark Eccleston called the notification "a significant milestone for Cytolytix, confirming the novelty of the platform", enabling "differentiated products for various routes of administration and across multiple clinical applications".

Granted patents are the currency ValiRx needs to attract outside money into Cytolytix without leaning on its own thin balance sheet. Management has said the intellectual property is intended to support licensing, partnering and external Investment in the subsidiary.

What ValiRx does now

ValiRx (LSE:VAL) describes itself as a Drug Development company focused on early-stage oncology and women's health. Its model changed materially in 2025. Rather than funding long clinical programmes centrally, it signs short evaluation agreements, typically three to six months, with universities and biotechs, tests the science at its Inaphaea BioLabs unit, and either walks away or exercises an option to license the asset into a special purpose vehicle that third parties can fund.

Assets sit in a series of subsidiaries. Cytolytix holds the CLX001 peptide programme. Blue Ribbon Bio houses VAL201, the legacy prostate cancer candidate, being redesigned as "VAL201 2.0". VAL401 was out-licensed to Ambrose Healthcare in 2025 for roughly 4.9% of Ambrose's equity, milestones of up to £16m and royalties. ValiRx Animal Health, formed in March 2026, targets veterinary oncology. Inaphaea holds a patient-derived cell biobank of more than 5,000 vials and runs the "3K Screen" programme with Dominion Biotech, which has identified more than 250 lead hits. Revenue is negligible; value creation depends on licensing deals and SPV Equity stakes rather than product sales.

FY2025 results: losses widen, costs fall, Going Concern flagged

Final results for the year to 31 December 2025, published on 22 June 2026, showed revenue of just £31,372, down from £49,775 in 2024. The operating loss widened to £2.42m from £2.14m and the loss before tax was £2.42m against £2.13m, reflecting write-downs of intangibles, with VAL201 carried at 60% and VAL401 at 70% of prior-year values. Basic loss per share fell to 0.54p from 1.45p, but only because successive placings swelled the share count.

Underlying costs did come down. Administrative expenses fell by £326,577 to £1.59m and Research and Development spend was £229,378, with a further £42,500 of annualised savings from salary cuts and advisory board changes after the year end. Net assets were £2.40m at 31 December 2025, down from £3.92m.

Year-end cash was £791,612, against £1.56m a year earlier. In May 2026 the company raised £1.155m gross through a placing, subscription and oversubscribed WRAP retail offer at 0.2p per share, a 17% discount to the prior close, with one-for-one warrants exercisable at 0.28p. The auditors highlighted a material uncertainty over going concern, and the directors stated the group remains "reliant on future fund raisings to continue their activities as budgeted". No Dividend is paid.

What could move the shares from here

The most visible near-term catalyst is the McGill and IRICoR asset. On 1 June 2026 ValiRx exercised its option over an orally available RNA helicase inhibitor after Inaphaea finished the evaluation four months early. The plan is to license it into a Canadian NewCo, with ValiRx contributing £150,000 for initial pre-clinical work in exchange for equity, and external investors, described as being in due diligence, providing up to £2m of seed funding in tranches. Definitive agreements and a funding announcement would be the first real proof point for the SPV model.

For Cytolytix, the next steps are lead-formulation selection from four candidate formats, cGMP manufacture and any deal built on the new patents. Blue Ribbon's VAL201 2.0 constructs are at Inaphaea for benchmarking, with patent filings and funder discussions flagged. The Dominion "PredictRx" licence, the 3K Screen hits and grant applications offer further newsflow. Half-year results to 30 June 2026, due around late September on last year's timetable, will show how quickly cash is being consumed.

Risks investors should watch

Funding risk dominates. The FY2025 accounts carry an explicit going-concern uncertainty, and with roughly £0.8m of cash at the year end plus £1.155m raised gross in May against an annual operating loss of about £2.4m, another equity raise within twelve months looks probable unless SPV funding or licensing income arrives. Each raise has been discounted and heavily dilutive: the share count reached 1.32 billion after the May placing, and 631 million warrants at 0.28p now overhang the register.

At 0.14p on 2 September 2026, the shares trade below the 0.2p placing price and near the 52-week low of 0.135p, and a market capitalisation of around £1.85m limits institutional interest and liquidity.

Execution risk is high. Evaluations with Imperial College, Stingray Bio and, on 22 June 2026, the University of Dundee were all terminated without an option being exercised. The SPV strategy relies on third-party investors not yet publicly confirmed, and VAL401 milestones depend entirely on Ambrose Healthcare. The team is small after three senior roles were lost in 2025 and non-executive director Dr Cathy Tralau-Stewart left following the July 2026 AGM.

Outlook

ValiRx enters the second half of 2026 with more intellectual property, a leaner cost base and a clearer model than a year ago, but with very little Margin for delay. The items to monitor are concrete: definitive agreements and external seed money for the McGill NewCo, a formulation decision and partnering news at Cytolytix, the interim cash figure, and whether any further funding round can be completed at or above the current price. Delivery would validate the pivot; slippage would return the focus squarely to survival.